222
Views
21
CrossRef citations to date
0
Altmetric
Research Articles

Expression levels of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and focal adhesion kinase in patients with multiple myeloma and their relationship to clinical stage and extramedullary infiltration

, , , , , , , & show all
Pages 1162-1168 | Received 27 Aug 2011, Accepted 03 Dec 2011, Published online: 31 Jan 2012
 

Abstract

We explored the expression of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and focal adhesion kinase (FAK) mRNA and protein, and analyzed the relationship between expression levels and clinical staging and extramedullary infiltration in patients with multiple myeloma (MM). The expression levels of mRNA and protein were measured by fluorescence quantitative polymerase chain reaction (FQ-PCR) and Western blotting. Expressions of PTEN and FAK mRNA were significantly different between patients with MM and controls. Spearman bivariate correlation analysis showed that PTEN mRNA was significantly negatively correlated with FAK mRNA. PTEN and FAK mRNA expressions were significantly different between patients with stage I + II MM and stage III MM. No difference was found in PTEN mRNA expression, whereas FAK mRNA expression was significantly different between patients with MM with and without extramedullary infiltration. PTEN protein was higher and total FAK (T-FAK) protein was significantly lower in six controls than in 12 patients with stage III MM. Phosphorylated FAK (p-FAK) protein was measured as 0.082 ± 0.040 in 11 patients with MM, but not detected in six controls. No significant difference of PTEN and T-FAK protein was found, while p-FAK protein was significantly different between patients with MM with and without extramedullary infiltration. These results indicate that abnormal expression of PTEN and FAK in patients with MM may be associated with disease progression and extramedullary infiltration.

Potential conflict of interest:

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.